In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AvidBiotics Corp.

http://www.avidbiotics.com

Latest From AvidBiotics Corp.

Astellas Strengthens Next-Gen I-O Hand With $665m Xyphos Buy

Astellas pays to play in next-generation immuno-oncology through deal for young, privately held US venture and its novel modulation platform.

M & A ImmunoOncology

Mining The Microbiome: Are Gut Microbes The Next Big Source Of Drugs?

There is growing interest in the gut microbiome as a source of new therapies across a wide range of diseases. Although it is still an emerging field, pharmaceutical firms and other investors are engaging, with more expected to follow.

BioPharmaceutical

Too Early For Tools?

Advances in high-throughput screening and metagenomic data analysis have already helped uncover the microbiome’s potential as a source of new therapeutic approaches. But more new tools will be needed to further decipher it.

BioPharmaceutical

Antibiotics: Officially Encouraged, Increasingly Precise, Still Risky

Anti-infective start-ups getting funded these days say they can boost the odds of clinical success, and reduce the cost of achieving it. Profiles of EnBiotix, Nosopharm, and Spero Therapeutics.

BioPharmaceutical
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register